19% Weight Loss: New Drug Approval Update (Europe)

19% Weight Loss: New Drug Approval Update (Europe)

European regulators have expanded the approval for Wegovy, a medication used for weight management, allowing for a higher dosage regimen. The decision, made by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), builds on a prior recommendation in December 2025 and offers a potentially more effective treatment option … Read more

Endometriosis: New Diagnosis & Treatment Guidelines Explained by UW Medicine Expert

Endometriosis: New Diagnosis & Treatment Guidelines Explained by UW Medicine Expert

Novel clinical guidance from the American College of Obstetricians & Gynecologists (ACOG) aims to shorten the often lengthy diagnostic journey for endometriosis, a chronic inflammatory condition affecting millions. The updated recommendations, published in February 2026, emphasize diagnosing the condition based on symptoms and imaging, and initiating treatment sooner when appropriate. This shift in approach could … Read more

Tattoos & Melanoma Risk: Swedish Study Findings

A growing body of research is examining the potential long-term health effects of tattoos, a practice that has surged in popularity in recent decades. A latest epidemiological study conducted in Sweden suggests a possible link between having tattoos and an increased risk of cutaneous melanoma, the most dangerous form of skin cancer. While the findings … Read more

Alzheimer’s: New Drug Reprograms Brain Cells, Shows Promise in Animal Studies

Alzheimer’s: New Drug Reprograms Brain Cells, Shows Promise in Animal Studies

Barcelona, Spain – Researchers at the University of Barcelona have developed and validated a novel compound, FLAV-27, that demonstrates the potential to reverse cognitive impairment in animal models of Alzheimer’s disease. Unlike existing treatments that primarily focus on removing amyloid plaques, this experimental drug targets the underlying epigenetic mechanisms contributing to the disease’s progression, offering … Read more